治疗治疗儿童和青少年的支气管切除症:一个简短的叙述审查
Paola Faverio1,2, Giovanni Franco1,2, Valentina Landoni1,2
1School of Medicine and Surgery, University of Milano-Bicocca, 20854 Monza, Italy.
Journal of clinical medicine
|August 29, 2024
概括
儿科支气管病的治疗包括气道清除,药物和疫苗接种. 多学科的方法是优化治疗和改善儿童的治疗结果的关键.
科学领域:
- 儿科肺病学 儿科肺病学
- 呼吸系统医学 呼吸系统医学
- 临床治疗学 临床治疗学
背景情况:
- 支气管切除症越来越多地在儿童和青少年中被诊断出来,其特征是气道扩张和粘液问题.
- 欧洲呼吸学会 (ERS) 和TSANZ的指导方针强调了儿童支气管病的早期诊断和优化管理.
研究的目的:
- 审查儿童支气管病的当前治疗策略.
- 为医疗保健专业人员提供基于证据的管理选项概述.
主要方法:
- 在PubMed和EMBASE数据库中进行全面的文献搜索,直到2023年12月.
- 包括观察性研究,干预,审查和指导方针,重点关注儿科支气管病.
主要成果:
- 治疗包括呼吸道清除,粘膜活性剂,肺部康复,支气管扩展剂和吸入性皮质类固醇.
- 抗生素对于预防和管理恶化至关重要,并考虑长期预防 (例如,宏类药物).
- 疫苗接种 (肺炎球菌,流感) 是至关重要的;手术/移植是严重病例的选择.
结论:
- 最佳的儿科支气管切除症护理需要一个多学科的方法,整合物理治疗,药物治疗和疫苗接种.
- 针对性,以指导方针为导向的管理对于改善受影响儿童的结果至关重要.
- 需要进一步的研究来完善诊断和治疗策略.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
Cystic Fibrosis: Management
146
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
146
Drugs Used in Lower Respiratory Disorders: Overview
362
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
362
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: β2-Adrenoceptor Agonists
239
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
239


